5 New Questions To Ask Before Signing With A Biologics CDMO

By Abby Sorensen, Marketing Manager, Scorpius BioManufacturing

The contract development and manufacturing organization (CDMO) sector has undergone significant changes, requiring a new approach to selecting a CDMO for biologics manufacturing. In the past, CDMOs focused on efficiency and capacity management for established products. However, with the emergence of novel therapeutic constructs, CDMOs now play a crucial role in scaling innovation and enabling the development of innovative therapeutic products. This evolution demands a reframing of successful partnership criteria.

When choosing a biologics CDMO partner, it is important to consider their capabilities expansion roadmap, their ability to support different phases of biologics development, their regulatory filing experience, cultural fit, and their team's ability to enhance the development effort. Today's CDMOs curate cutting-edge expertise, supporting innovators through every stage of development. They possess the agility to adapt to unpredictable timelines, the flexibility to handle small batches, and the vision to anticipate future needs. Outsourcing is now more than just manufacturing; it's a true collaboration in which innovators and CDMOs co-create the future of medicine.

Explore how a leading CDMO, dedicated to scaling biotherapeutic advancements and supporting innovation, and equipped with a highly experienced team, can help sponsor companies unlock the full potential of their biotherapeutics, transforming lives and redefining the future of healthcare.